Uwe Platzbecker, Prof.
Universitätsklinikum Leipzig · University of Leipzig · University Leipzig
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Uwe Platzbecker, Prof. as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:23 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06243458 · RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic NeoplasmsGCP-Service International West GmbH · active not recruiting · Low Risk Myelodysplastic Syndromes · principal investigator
- Ph2NCT05829434 · Magrolimab Plus Intensive Chemotherapy in Newly Diagnosed AML or HR-MDSUwe Platzbecker · withdrawn · Acute Myeloid Leukemia, Myelodysplastic Neoplasm · principal investigator
- Ph2NCT05178342 · Treatment of Anemia in Patients With Very Low, Low or Intermediate Risk Myelodysplastic Syndromes With CA-4948University of Leipzig · terminated · Myelodysplastic Syndromes, Anemia · principal investigator
- Ph2NCT04712942 · Treatment of MDS/AML Patients With an Impending Hematological Relapse With AZA or ATA and PevonedistatUniversity of Leipzig · completed · Acute Myeloid Leukemia in Remission, Myelodysplastic Syndromes, Minimal Residual Disease · principal investigator
- Ph2NCT04061239 · Comparison of Therapies Before Stem Cell Transplantation in Patients With Higher Risk MDS and Oligoblastic AMLGWT-TUD GmbH · completed · MDS, AML · study chair
- Ph2NCT03824080 · Evaluating the Efficacy and Safety of Bemcentinib in Patients With Myelodysplastic SyndromesGWT-TUD GmbH · completed · Acute Myeloid Leukemia, High-risk Myelodysplastic Syndrome, Low-risk Myelodysplastic Syndrome · principal investigator
- Ph2NCT02992860 · Single Agent JNJ-56022473 in MDS and AML Patients FAILING HYPOMETHYLATING AGENT BASED THERAPYGWT-TUD GmbH · terminated · Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML) · principal investigator
- Ph3NCT02688140 · Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic LeukemiaTechnische Universität Dresden · completed · Acute Promyelocytic Leukemia · principal investigator
- Ph2NCT02446145 · A Randomized Placebo-controlled Phase 2 Study of Decitabine With or Without Eltrombopag in AML PatientsTechnische Universität Dresden · terminated · Acute Myeloid Leukemia · principal investigator
- Ph2NCT02335268 · Validation of a Predictive Model of Response to Romiplostim in Patients With IPSS Low or Intermediate-1 Risk MDS and ThrombocytopeniaGesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH · completed · Myelodysplastic Syndromes · study director
- Ph2NCT01462578 · Treatment of Patients With Myelodysplastic Syndrome or Acute Myelocytic Leukemia With an Impending Hematological Relapse With Azacitidine (Vidaza)Technische Universität Dresden · completed · Acute Myelocytic Leukemia, Myelodysplastic Syndrome · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:23 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in acute myeloid leukemia.